SEC 13F Intelligence

Managers / Q4 2025 · view latest →

Octagon Capital Advisors LP

CIK 0001839435 · 654 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10065 · 212-369-2829

Reported Value
$824M
Q4 2025
Positions
27
Filings on Record
23
2019–present window
Filed
Feb 17, 2026
original filing

Summary

Octagon Capital Advisors LP reported $824M in U.S.-listed holdings across 27 positions for Q4 2025.

Its largest position, ABVX, represents 12.4% of the portfolio.

Compared with Q3 2025, the fund opened 8 new positions and exited 7.

Portfolio Metrics

Turnover
+13.3%
vs prior filed quarter
Top-10 Concentration
+67.4%
share of reported value
Largest Position
+12.4%
Abivax
New / Exited
8 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $288MQ4 ’20Q1 ’21: $265MQ2 ’21: $483MQ3 ’21: $406MQ3 ’21Q4 ’21: $514MQ1 ’22: $463MQ2 ’22: $375MQ2 ’22Q3 ’22: $579MQ4 ’22: $642MQ1 ’23: $695MQ1 ’23Q2 ’23: $719MQ3 ’23: $651MQ4 ’23: $625MQ4 ’23Q1 ’24: $834MQ2 ’24: $636MQ3 ’24: $643MQ3 ’24Q4 ’24: $608MQ1 ’25: $517MQ2 ’25: $456MQ2 ’25Q3 ’25: $660MQ4 ’25: $824MQ1 ’26: $904MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.7%ADR: 16.0%Other: 2.3%
  • Common Stock · 81.7% · $673M
  • ADR · 16.0% · $132M
  • Other · 2.3% · $19M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CGONCG ONCOLOGY INCNEW+600.0K600.0K+$25M$25M
ALMSALUMIS INCNEW+2.53M2.53M+$25M$25M
PALIPALISADE BIO INCNEW+9.57M9.57M+$22M$22M
BIOABIOAGE LABS INCNEW+1.60M1.60M+$21M$21M
RAPTRAPT THERAPEUTICS INCNEW+574.0K574.0K+$19M$19M
LXEOLEXEO THERAPEUTICS INCNEW+1.73M1.73M+$17M$17M
EVMNEVOMMUNE INCNEW+500.0K500.0K+$9M$9M
DTILPRECISION BIOSCIENCES INCNEW+1.92M1.92M+$8M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ABVXABIVAX SAhistory →SPONSORED ADS12.38%$102M756.0K
2DNTHDIANTHUS THERAPEUTICS INChistory →COM12.09%$100M2.42M
3COGTCOGENT BIOSCIENCES INChistory →COM10.13%$83M2.35M
4TSHATAYSHA GENE THERAPIES INChistory →COM SHS5.92%$49M8.86M
5GOSSGOSSAMER BIO INChistory →COM5.24%$43M13.92M
6KYMRKYMERA THERAPEUTICS INChistory →COM5.05%$42M535.0K
7AVBPARRIVENT BIOPHARMA INChistory →COM4.81%$40M1.97M
8TRVITREVI THERAPEUTICS INChistory →COM4.28%$35M2.81M
9OCULOCULAR THERAPEUTIX INChistory →COM3.87%$32M2.62M
10BRD1EURMIND MEDICINE MINDMED INChistory →COM NEW3.63%$30M2.23M
11ALMSALUMIS INChistory →COM3.00%$25M2.53M
12PALIPALISADE BIO INChistory →COM2.73%$22M9.57M
13CDTXCIDARA THERAPEUTICS INChistory →COM NEW2.68%$22M100.0K
14BIOABIOAGE LABS INChistory →COM2.57%$21M1.60M
154XC1KALVISTA PHARMACEUTICALS INChistory →COM2.50%$21M1.27M
16RAPTRAPT THERAPEUTICS INChistory →COM NEW2.36%$19M574.0K
17260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS2.28%$19M750.0K
18PHARVARIS N VCOM2.26%$19M671.5K
19LXEOLEXEO THERAPEUTICS INChistory →COM2.08%$17M1.73M
20BBOTBRIDGEBIO ONCOLOGY THERAPEUThistory →COM NEW1.59%$13M1.04M
21DBVTDBV TECHNOLOGIES S Ahistory →SPONSORED ADS1.34%$11M574.2K
22EVMNEVOMMUNE INChistory →COM SHS1.04%$9M500.0K
23DTILPRECISION BIOSCIENCES INCCOM NEW0.97%$8M1.92M
24CRBPCORBUS PHARMACEUTICALS HLDGSCOM NEW0.94%$8M955.0K
25UNCYUNICYCIVE THERAPEUTICS INCCOM NEW0.70%$6M1.00M
26PEPGPEPGEN INCCOM0.55%$5M700.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$904M29May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$824M27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$660M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$456M30Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$517M35May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$608M33Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$643M42Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$636M47Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$834M57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$625M33Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$651M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$719M41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$695M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$642M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$579M35Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$375M20Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$463M24May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$514M28Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$406M30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$483M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$265M28May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$288M31Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.